OCM
TNGX icon

Ovata Capital Management’s Tango Therapeutics TNGX Stock Holding History

Ovata Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-900
Closed -$7K – 134
2022
Q1 		$7K Buy
+900
New +$7.8K ﹤0.01% 125

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Ovata Capital Management's TNGX Position: Q2 2022 in Review

Ovata Capital Management sold out of Tango Therapeutics (TNGX) in Q2 2022, closing a stake of 900 shares — an estimated $7K sold.

Ovata Capital Management first reported a position in TNGX in Q1 2022 and held it in 1 quarter. The position peaked at $7K in Q1 2022. 77 funds tracked by Wall St. Rank hold TNGX as of Q2 2022.

  • Ovata Capital Management reported no remaining Tango Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ovata Capital Management sold 900 Tango Therapeutics shares in Q2 2022, an estimated $7K.
  • Ovata Capital Management first reported a position in Tango Therapeutics in Q1 2022 and held it in 1 quarter.
  • Ovata Capital Management's Tango Therapeutics position peaked at $7K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2022.

Based on Ovata Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.